Detalles de la búsqueda
1.
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
Haematologica
; 2024 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38497158
2.
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
Haematologica
; 2024 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38385243
3.
Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim.
Ann Hematol
; 103(3): 947-956, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38189833
4.
Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study).
Hematol Oncol
; 40(4): 609-616, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35612350
5.
MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients.
Br J Haematol
; 195(3): 399-404, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34318932
6.
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.
Ann Hematol
; 100(10): 2547-2556, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34327561
7.
Association between CMV and Invasive Fungal Infections After Autologous Stem Cell Transplant in Lymphoproliferative Malignancies: Opportunistic Partnership or Cause-Effect Relationship?
Int J Mol Sci
; 20(6)2019 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-30893777
8.
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Br J Haematol
; 183(5): 755-765, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30407629
9.
Lenograstim 5 µg/kg is not superior to biosimilar filgrastim 10 µg/kg in lymphoma patients undergoing peripheral blood stem cell mobilization after chemotherapy: preliminary results from a prospective randomized study.
Transfusion
; 58(5): 1143-1148, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29446445
10.
Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant.
Chemotherapy
; 62(1): 58-61, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-27618144
11.
Endothelial dysfunction and high cardiovascular risk profile in severe alcoholics improve only partially following a medium-term alcohol withdrawal.
Alcohol Clin Exp Res
; 36(2): 242-50, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22013918
12.
Reverse strategy to locally advanced breast implant-associated anaplastic large cell lymphoma: A case report.
Front Oncol
; 12: 1062389, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36703782
13.
Flow cytometry characterization in central nervous system and pleural effusion multiple myeloma infiltration: an Italian national cancer institute experience.
Br J Haematol
; 172(6): 980-2, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26081466
14.
Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network.
Br J Haematol
; 169(2): 293-6, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25371286
15.
Role of Pregabalin in Treatment of Polyneuropathy in Multiple Myeloma Patients: A Retrospective Study.
Clin Neuropharmacol
; 42(5): 167-171, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31361668
16.
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network 'Rete Ematologica del Lazio per i Linfomi' (RELLI).
Leuk Lymphoma
; 60(14): 3386-3394, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31259651
17.
Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
J Exp Clin Cancer Res
; 37(1): 95, 2018 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29716630
18.
Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas.
Leukemia
; 36(2): 588-590, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34545184
19.
Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study.
J Exp Clin Cancer Res
; 35: 49, 2016 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-26992692
20.
Cytomegalovirus reactivation after autologous stem cell transplantation in myeloma and lymphoma patients: A single-center study.
World J Transplant
; 5(3): 129-36, 2015 Sep 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-26421265